Imatinib, an inhibitor of BCR-ABL tyrosine kinase inhibitors (TKI) and the first-line chemotherapeutic drug for most patients with chronic myelogenous leukemia (CML) (Braun et al., 2020; Moslehi and Deininger, 2015), exhibits an effective inhibition on KIT kinase activity (Guida et al., 2007; Heinrich et al., 2000), implying its potential therapeutic application to the KIT-mutated AML patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.